Virus-like Particle Display of the α-Gal Carbohydrate for Vaccination against Leishmania Infection
نویسندگان
چکیده
Secreted and surface-displayed carbohydrates are essential for virulence and viability of many parasites, including for immune system evasion. We have identified the α-Gal trisaccharide epitope on the surface of the protozoan parasites Leishmania infantum and Leishmania amazonensis, the etiological agents of visceral and cutaneous leishmaniasis, respectively, with the latter bearing larger amounts of α-Gal than the former. A polyvalent α-Gal conjugate on the immunogenic Qβ virus-like particle was tested as a vaccine against Leishmania infection in a C57BL/6 α-galactosyltransferase knockout mouse model, which mimics human hosts in producing high titers of anti-α-Gal antibodies. As expected, α-Gal-T knockout mice infected with promastigotes of both Leishmania species showed significantly lower parasite load in the liver and slightly decreased levels in the spleen, compared with wild-type mice. Vaccination with Qβ-α-Gal nanoparticles protected the knockout mice against Leishmania challenge, eliminating the infection and proliferation of parasites in the liver and spleen as probed by qPCR. The α-Gal epitope may therefore be considered as a vaccine candidate to block human cutaneous and visceral leishmaniasis.
منابع مشابه
Vaccination against Mosquito Borne Viral Infections: Current Status
Mosquito borne infectious diseases are among important group of diseases worldwide. Vaccination is available for some tropical mosquito-borne diseases, especially for Japa-nese encephalitis virus infection and yellow fever. There are also several attempts to develop new vaccines for the other mosquito-borne diseases such as malaria, dengue infection and West Nile virus infection. In this articl...
متن کاملRole of imiquimod as adjuvant for vaccination against Leishmania major infection in BALB/c mice
Various adjuvants in combination with different antigens have been utilized as a vaccine candidate against leishmaniasis. However, the search for ideal adjuvants is still pursued due to the inefficiencies of current compounds. In the present study, the effect of imiquimod, as an adjuvant, is studied with soluble Leishmania antigens (SLA) in BALB/c mice. Four groups of mice were immunized with S...
متن کاملAn α-Gal-containing neoglycoprotein-based vaccine partially protects against murine cutaneous leishmaniasis caused by Leishmania major
BACKGROUND Protozoan parasites from the genus Leishmania cause broad clinical manifestations known as leishmaniases, which affect millions of people worldwide. Cutaneous leishmaniasis (CL), caused by L. major, is one the most common forms of the disease in the Old World. There is no preventive or therapeutic human vaccine available for L. major CL, and existing drug treatments are expensive, ha...
متن کاملEvaluation of Antibodies against Rubella Virus in a Mass Campaign Vaccination in Tehran, Iran
Background and Aims: Vaccine is available, but fetal infection with rubella virus is still a main cause of congenital birth defects and mental retardation in many countries. Mass vaccination campaigns and Expanded Program of Immunization (EPI) have increased vaccine coverage in the world with a substantial impact on the reduction of rubella infections, such as Congenital Rubella Syndrome (CRS)....
متن کاملTLR1/2 Activation during Heterologous Prime-Boost Vaccination (DNA-MVA) Enhances CD8+ T Cell Responses Providing Protection against Leishmania (Viannia)
BACKGROUND Leishmania (Viannia) parasites present particular challenges, as human and murine immune responses to infection are distinct from other Leishmania species, indicating a unique interaction with the host. Further, vaccination studies utilizing small animal models indicate that modalities and antigens that prevent infection by other Leishmania species are generally not protective. MET...
متن کامل